GlassScriptPhysician profile
Boris Sagalovich
NPI 1346391174
$211,786.49
in general payments reported to CMS, 2019-2025
50 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $30K · 2021: $26K · 2022: $18K · 2023: $26K · 2024: $30K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Food and Beverage: $14K · Travel and Lodging: $3,295 · Education: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,678.00 |
| Food and Beverage | $13,513.76 |
| Travel and Lodging | $3,294.69 |
| Education | $584.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $74,506.68 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $49,368.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36,269.58 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Insmed, INC. | $14,897.81 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $9,296.24 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $6,108.95 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $3,621.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $3,116.90 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Harmony Biosciences LLC | $1,910.52 | 2020-2025 | Wakix |
| Genentech USA, INC. | $1,762.34 | 2019-2024 | Xolair |
| Jazz Pharmaceuticals INC. | $1,384.85 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $994.82 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $816.33 | 2019-2025 | Opsumit, Uptravi |
| Electromed, INC. | $730.96 | 2019-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $644.32 | 2019-2024 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $600.00 | 2019 | |
| Advanced Respiratory, INC | $560.15 | 2019-2021 | |
| Axsome Therapeutics, INC. | $550.26 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $485.45 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $395.61 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Amgen INC. | $368.97 | 2022-2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $342.01 | 2019 | |
| Mallinckrodt Hospital Products INC. | $312.53 | 2020-2025 | Acthar |
| Verona Pharma, INC. | $256.31 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $251.49 | 2025 | Inspire |
| Pfizer INC. | $247.01 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.27 | 2019-2025 | |
| Inogen, INC. | $229.15 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| United Therapeutics Corporation | $206.15 | 2021-2023 | Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $182.95 | 2024-2025 | Lumryz |
| Teva Pharmaceuticals USA, INC. | $172.68 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.23 | 2023-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $132.99 | 2023-2025 | |
| Baxter Healthcare | $107.23 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $78.16 | 2024-2025 | Purified Cortrophin Gel |
| Optinose US, INC. | $70.22 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.82 | 2022-2024 | Glassia |
| Paratek Pharmaceuticals, INC. | $54.90 | 2024 | Nuzyra |
| Viatris Specialty LLC | $53.01 | 2025 | Yupelri |
| Gilead Sciences, INC. | $44.00 | 2019 | |
| Vifor Pharma, INC. | $35.55 | 2025 | Veltassa, Zemaira |
| Circassia INC. | $31.29 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.23 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.26 | 2025 | Alvesco |
| Horizon Therapeutics Plc | $20.83 | 2020 | |
| Nabriva Therapeutics, Plc | $20.33 | 2021 | |
| Hikma Pharmaceuticals USA | $17.62 | 2022 | |
| Merck Sharp & Dohme LLC | $17.00 | 2021 | |
| Lilly USA, LLC | $16.00 | 2025 | Zepbound, Mounjaro |
| Olympus America INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Sagalovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.